Cord Blood Banking Market Sees Growth

The U.S. Food and Drug Administration (FDA) has approved the use of cord blood stem cells for the treatment of more than 80 diseases. These include a range of cancers like leukemias and lymphomas, as well as blood disorders such as sickle cell anemia, thalassemia, and aplastic anemia. There are two primary models for cord blood banking: public and private. Public banks accept donations for free, making the stem cells available to any matching patient in need, similar to a blood bank. Private banks charge fees to store the cord blood for the exclusive use of the donor's family. The cost of private banking typically includes an initial fee between $1,500 and $3,000, with annual storage fees ranging from $150 to $300. While donating to a public bank costs nothing, retrieving a unit for a transplant from a public bank can be expensive, with costs around $45,000. A key area of research is cord blood expansion, a technology that aims to multiply the number of stem cells from a single collection. This is critical for overcoming one of the main limitations of cord blood—the cell dose, which is often insufficient for treating adult patients who require more stem cells than children. Globally, more than 40,000 cord blood transplants have been performed. The market is led by major players like Cord Blood Registry (CBR) Systems, Cryo-Cell International, and ViaCord in the United States. While North America is the largest market, Europe and the Asia-Pacific region are experiencing significant growth. Key international players include FamiCord, the largest network in Europe, and CryoHoldco, a market leader in Latin America. Beyond established treatments, hundreds of clinical trials are underway to explore the use of cord blood stem cells in regenerative medicine for conditions like type 1 diabetes, cerebral palsy, and cardiac repair.